- Home
- TWO vs RCUS Comparison
TWO vs RCUS Comparison
Compare TWO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- RCUS
- Stock Information
- Founded
- TWO 2009
- RCUS 2015
- Country
- TWO United States
- RCUS United States
- Employees
- TWO N/A
- RCUS N/A
- Industry
- TWO Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- RCUS Health Care
- Exchange
- TWO Nasdaq
- RCUS Nasdaq
- Market Cap
- TWO 1.3B
- RCUS 1.2B
- IPO Year
- TWO 2009
- RCUS 2018
- Fundamental
- Price
- TWO $13.77
- RCUS $11.07
- Analyst Decision
- TWO Buy
- RCUS Buy
- Analyst Count
- TWO 8
- RCUS 11
- Target Price
- TWO $14.04
- RCUS $31.11
- AVG Volume (30 Days)
- TWO 1.2M
- RCUS 1.1M
- Earning Date
- TWO 01-29-2025
- RCUS 02-25-2025
- Dividend Yield
- TWO 13.08%
- RCUS N/A
- EPS Growth
- TWO N/A
- RCUS N/A
- EPS
- TWO 2.37
- RCUS N/A
- Revenue
- TWO $622,055,000.00
- RCUS $263,000,000.00
- Revenue This Year
- TWO N/A
- RCUS $127.65
- Revenue Next Year
- TWO N/A
- RCUS N/A
- P/E Ratio
- TWO $5.80
- RCUS N/A
- Revenue Growth
- TWO 130.86
- RCUS 119.17
- 52 Week Low
- TWO $10.84
- RCUS $10.63
- 52 Week High
- TWO $14.27
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- TWO 76.81
- RCUS 34.34
- Support Level
- TWO $13.45
- RCUS $10.63
- Resistance Level
- TWO $13.67
- RCUS $13.49
- Average True Range (ATR)
- TWO 0.19
- RCUS 0.77
- MACD
- TWO 0.07
- RCUS -0.13
- Stochastic Oscillator
- TWO 91.10
- RCUS 13.88
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust primarily focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. Most of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.